Pfizer Inc (PFE): Capital Expenditures
$2.63B
Year ended 2025-12-31
$2.42B
Trailing 12 months to 2026-06-28
-6.7%
3-year compound annual growth
+3.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.63B | -9.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $2.91B | -25.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $3.91B | +20.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $3.24B | +19.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $2.71B | +21.8% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $2.23B | +8.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $2.05B | n/c | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $1.98B | n/c | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $1.96B | +7.3% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $1.82B | +30.5% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $1.40B | +16.5% | 2018-02-22, From 2015-01-01 |
| 2014-12-31 | $1.20B | -0.6% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $1.21B | -9.1% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $1.33B | -20.1% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $1.66B | +9.7% | 2014-02-28, From 2011-01-01 |
| 2010-12-31 | $1.51B | +25.6% | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | $1.21B | -29.2% | 2012-02-28, From 2009-01-01 |
| 2008-12-31 | $1.70B | -9.5% | 2011-02-28, From 2008-01-01 |
| 2007-12-31 | $1.88B | n/a | 2010-02-26, From 2007-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $1.21B | +24.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $378.80M | +16.2% |
Compare PFE, ABBV, MRK, BMY side by side · Screen every company in Pharmaceutical Preparations ↗